As biologics have grown to dominate the market in the past decade, the threat to established pharmaceuticals is no longer generics, it’s biosimilars. First look at the evolution of pharma’s blockbuster drugs. Then see the top drugs by molecule type, therapy area and how biologics have grown in the last decade, to get a clearer picture of how the golden age of the first wave of monoclonal antibodies is waning. This Scrip infographic also shows the new US and UK biosimilars on the horizon with a clear scan of the launch dates and companies and current drugs in their cross hairs.